The incidence of adverse reactions was classified as follows: very often (≥1/10), often (≥1 / 100, <1/10), infrequently (≥1 / 1000, <1/100),rarely (≥1 / 10000, <1/1000), very rarely (<1/10000), the frequency is not established (there is currently no data on the prevalence of adverse reactions).
Infectious and parasitic diseases: infrequently - fungal infections.
From the immune system: often - a hypersensitivity to memantine or other components that make up the drug.
Disorders of the psyche: infrequently - confusion, hallucinations (mainly in patients with severe Alzheimer's disease); frequency is not established - psychotic reactions.
From the nervous system: often - headache, drowsiness, dizziness, imbalance; infrequently - gait disturbance; very rarely - seizures, epileptic seizures;
From the heart: infrequently - heart failure, heart defects.
From the side of the vessels: often - increased blood pressure, venous thrombosis and / or thromboembolism.
From the respiratory system of the chest and mediastinum: often - shortness of breath.
From the gastrointestinal tract: often constipation; rarely - nausea, vomiting; frequency not established - pancreatitis.
From the liver and bile ducts: often - a violation of functional liver tests.
Other: infrequently fatigue, general weakness.
In Alzheimer's disease, depression, suicidal thoughts and suicide cases were recorded in post-marketing studies.
In the postmarketing period, the following adverse reactions were reported: agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombocytopenic purpura, hepatitis, acute renal failure, Stevens-Johnson syndrome.